Financial results of Q2 2023 Net sales decrease organically by −1.1% to € 5.3 billion EBITDA pre down organically by −7.0% t...
-Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of...
Product Sales Excluding Veklury Increased 11% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 17% Year-Over-Year to $3.0 billion Oncology Sales...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22...
Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022. On a curre...
SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/MAPK pathway to regulate cellular ...
he three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies, including any allegations related ...
“Agilent is committed to our customers’ success at every stage of their journey to bring great science to life,” said Agilent President a...
Each year, millions of patients contract infectious diseases while in hospital. These HAIs not only lengthen hospital stays and utilize resources, such as ...
Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that the companies have agreed ...
Collaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusiv...
Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications including ongoing ...
Novel antibody specifically designed for oral administration utilizes Tillotts Pharma’s sustained release approach to ensure optimal and local trea...
© 2025 Biopharma Boardroom. All Rights Reserved.
